Login
Super Investors Merck & Co., Inc.
M&

Merck & Co., Inc.

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$820M
Positions
13
Quarter ended
September 30, 2026
Filed
November 13, 2026

Reported portfolio value by quarter (8 quarters reported)

$820M $164M
Q4 24 Q2 25 Q4 25 Q2 26 Q3 26

$258M in Q4 2024 → $820M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Moderna Inc 54.2% Unchanged 2,308,190 $444M
Personalis Inc 27.9% Unchanged 14,044,943 $229M
Kymera Therapeutics Inc 10.5% Unchanged 772,165 $86.3M
Aktis Oncology Inc 2.3% Unchanged 952,844 $18.6M
Eikon Therapeutics Inc 1.6% Unchanged 1,666,666 $13.4M
Entrada Therapeutics Inc 1.3% Unchanged 1,739,768 $11M
Alector Inc 0.8% Unchanged 3,545,719 $6.56M
Sutro Biopharma Inc 0.5% Unchanged 272,351 $4.39M
EA Evaxion As 0.5% Unchanged 1,214,126 $3.98M
VT Viridian Therapeutics Inc 0.2% Unchanged 93,414 $1.92M
Xilio Therapeutics Inc 0.1% Unchanged 105,982 $959K
Tuhura Biosciences Inc 0.0% Unchanged 19,445 $40.8K
Neuphoria Therapeutics Inc 0.0% Unchanged 10,027 $35.7K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 13, 2026

No position changes this quarter.

Q2 2026

quarter ended June 30, 2026 · filed August 07, 2026

Company Action Shares changed Value of change % of portfolio
Entrada Therapeutics Inc Exited −1,739,768 −$22M —
Entrada Therapeutics Inc New +1,739,768 +$12.8M 2.4%
Sutro Biopharma Inc New +272,351 +$9.04M 1.7%
Sutro Biopharma Inc Exited −272,351 −$6.78M —
Evaxion Biotech A/s Exited −1,214,126 −$4.52M —
Evaxion Biotech A/s New +1,214,126 +$3.76M 0.7%
Carisma Therapeutics Inc Exited −1,473,240 −$47.9K —

Q1 2026

quarter ended March 31, 2026 · filed May 13, 2026

Company Action Shares changed Value of change % of portfolio
Eikon Therapeutics Inc New +1,666,666 +$17.6M 5.0%
Aktis Oncology Inc New +952,844 +$17M 4.9%
Xilio Therapeutics Inc Exited −1,483,758 −$950K —
Xilio Therapeutics Inc New +105,982 +$891K 0.3%
Tuhura Biosciences Added +5,495 +$9.84K —

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
Sutro Biopharma Inc Trimmed −2,451,158 −$28.4M 1.1%
Lava Therapeutics Nv Exited −1,149,345 −$1.79M —

Q3 2025

quarter ended September 30, 2025 · filed November 12, 2025

No position changes this quarter.

Q2 2025

quarter ended June 30, 2025 · filed August 13, 2025

Company Action Shares changed Value of change % of portfolio
Tuhura Biosciences New +13,950 +$31.1K —

Q1 2025

quarter ended March 31, 2025 · filed May 14, 2025

Company Action Shares changed Value of change % of portfolio
Absci Corporation Exited −998,163 −$2.62M —
Evaxion Biotech A/s Added +671,847 +$1.24M 1.4%

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support